SCHEMBL1421898

SCHEMBL1421898

CCS(=O)(=O)Nc1ccc(CC(=O)O)cc1

nearest known ligand 0.65

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
HPGD P15428 7/20 0.65
LMNA P02545 2/20 0.65
HTT P42858 1/20 0.65
SMN1; SMN2 Q16637 1/20 0.65
GAA P10253 1/20 0.55
L3MBTL1 Q9Y468 2/20 0.54
MAPT P10636 1/20 0.54
ALDH1A1 P00352 2/20 0.54
POLB P06746 1/20 0.54
NR3C2 P08235 1/20 0.50
AR P10275 1/20 0.50
CYP26A1 O43174 3/20 0.49
FABP4 P15090 1/20 0.49
CYP26B1 Q9NR63 1/20 0.49
HSD17B10 Q99714 1/20 0.49
CASP6 P55212 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5452372 0.88 GAA (0.51) HPGDLMNAHTTSMN1; SMN2GAA
SCHEMBL4161796 0.84 HPGD (0.62) HPGDLMNAHTTSMN1; SMN2L3MBTL1
SCHEMBL1422207 0.84 ALDH1A1 (0.63) HPGDLMNAHTTSMN1; SMN2GAA
SCHEMBL398078 0.83 HPGD (0.57) HPGDLMNAHTTSMN1; SMN2GAA
SCHEMBL16799573 0.83 HPGD (0.61) HPGDLMNAHTTSMN1; SMN2L3MBTL1
SCHEMBL1422100 0.81 HPGD (0.66) HPGDLMNAHTTGAAMAPT
SCHEMBL28058280 0.80 GAA (0.56) GAAL3MBTL1ALDH1A1POLB
SCHEMBL12309811 0.79 HPGD (0.77) HPGDLMNAHTTSMN1; SMN2L3MBTL1
SCHEMBL3555917 0.78 HPGD (0.62) HPGDLMNAHTTSMN1; SMN2L3MBTL1
SCHEMBL1017480 0.78 HPGD (0.72) HPGDLMNAHTTSMN1; SMN2L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2015083130-A1 FUSED PYRIDINE AND PYRIMIDINE DERIVATIVES AS ROR GAMMA MODULATORS AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) 2015-06-11 WO disclosed
WO-2015083130-A1 FUSED PYRIDINE AND PYRIMIDINE DERIVATIVES AS ROR GAMMA MODULATORS AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) 2015-06-11 WO disclosed
US-20110177055-A1 COMPOUNDS AND COMPOSITIONS AS CHANNEL ACTIVATING PROTEASE INHIBITORS IRM LLC (BM) 2011-07-21 US disclosed
US-7939547-B2 Compounds and compositions as channel activating protease inhibitors IRM LLC (BM) 2011-05-10 US disclosed
EP-2019837-B1 COMPOUNDS AND COMPOSITIONS AS CHANNEL ACTIVATING PROTEASE INHIBITORS IRM LLC (BM) 2011-03-23 EP disclosed
CN-101443348-A Compounds and compositions as channel activating protease inhibitors IRM LLC (BM) 2009-05-27 CN disclosed
EP-2019837-A1 COMPOUNDS AND COMPOSITIONS AS CHANNEL ACTIVATING PROTEASE INHIBITORS IRM LLC (BM) 2009-02-04 EP disclosed
WO-2007140117-A1 COMPOUNDS AND COMPOSITIONS AS CHANNEL ACTIVATING PROTEASE INHIBITORS IRM LLC (BM) 2007-12-06 WO disclosed
US-20070276002-A1 Compounds and Compositions as Channel Activating Protease Inhibitors IRM LLC (BM) 2007-11-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070276002-A1 Compounds and Compositions as Channel Activating Protease Inhibitors PRSS1, PRSS8, PRSS2 HPGD 922/4885LMNA 1172/4885HTT 1584/4885
US-20110177055-A1 COMPOUNDS AND COMPOSITIONS AS CHANNEL ACTIVATING PROTEASE INHIBITORS PRSS1, PRSS8, PRSS2 HPGD 970/4885LMNA 1191/4885HTT 1578/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.